Inovio Pharmaceuticals, Inc.
INO
$2.04
$0.094.62%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 182.30K | 283.10K | 217.80K | 203.50K | 591.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 182.30K | 283.10K | 217.80K | 203.50K | 591.90K |
| Cost of Revenue | 62.23M | 70.80M | 75.62M | 79.99M | 76.76M |
| Gross Profit | -62.05M | -70.52M | -75.41M | -79.79M | -76.17M |
| SG&A Expenses | 33.80M | 35.45M | 36.99M | 34.94M | 36.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 96.03M | 106.25M | 112.62M | 114.93M | 113.01M |
| Operating Income | -95.85M | -105.96M | -112.40M | -114.72M | -112.42M |
| Income Before Tax | -87.76M | -96.48M | -107.25M | -112.88M | -121.64M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -87.76 | -96.48 | -107.25 | -112.88 | -121.64 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -87.76M | -96.48M | -107.25M | -112.88M | -121.64M |
| EBIT | -95.85M | -105.96M | -112.40M | -114.72M | -112.42M |
| EBITDA | -94.29M | -104.27M | -110.65M | -112.82M | -110.29M |
| EPS Basic | -2.66 | -3.24 | -4.03 | -4.49 | -5.11 |
| Normalized Basic EPS | -1.67 | -2.03 | -2.53 | -2.71 | -2.79 |
| EPS Diluted | -2.66 | -3.24 | -4.03 | -4.49 | -5.11 |
| Normalized Diluted EPS | -1.67 | -2.03 | -2.53 | -2.71 | -2.79 |
| Average Basic Shares Outstanding | 135.58M | 123.94M | 108.62M | 101.36M | 95.61M |
| Average Diluted Shares Outstanding | 135.58M | 123.94M | 108.62M | 101.36M | 95.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |